Moss, 04 December 2020<br />
<br />
Reference is made to the stock exchange release 04 December 2020 regarding the
Employee Share Purchase Program.  The Board of Gentian Diagnostics has resolved
to issue 9,171 shares to employees at an issue price of NOK 50.38 per share.<br
/>
<br />
Also, reference is made to the annual general meeting 28 May 2019 where a
statement of remuneration to key personnel was given. In accordance with this
statement the board of Gentian Diagnostics AS has allocated a total of 150,000
options to key employees under the existing option program.<br />
 <br />
The following number of shares and options have been allocated to primary
insiders of Gentian Diagnostics AS:<br />
<br />
Hilja Ibert, Chief Executive Officer: 397 shares. Following the allocations Ms.
Ibert hold 6,525 shares and 279,924 options in the Company.<br />
<br />
Njaal Kind, Group Chief Financial Officer: 397 shares and 40,000 options.
Following the allocations Mr. Kind hold 20,712 shares and 114,991 options in the
Company.<br />
<br />
Erling Sundrehagen, Chief Scientific Officer: 50,000 options. Following the
allocation Mr. Sundrehagen and related parties hold 184,083 shares and 100,000
options in the Company.<br />
<br />
Torsten Knüttel, Vice President R&D: 397 shares. Following the allocation Mr.
Knüttel hold 712 shares and 10,000 options in the Company.<br />
<br />
Jack Andreassen, Vice President Business Development: 397 shares and 20,000
options. Following the allocation Mr. Andreassen hold 3,972 shares and 20,000
options in the Company.<br />
<br />
Julie Gryga, Chief Financial Officer Gentian AS: 397 shares. Following the
allocation Ms. Gryga hold 627 shares in the Company.<br />
<br />
The exercise price for the options granted is NOK 62.88 being the average
volume-weighted share price on the Oslo Stock Exchange for the past 10 trading
days prior to 20 November. The right to exercise the options is vested over a
period of 3 years, with 1/3 of the options vesting by the end of each year as
follows: (i) 1/3 of the options granted, no earlier than 2 years after the
allocation date (ii) 1/3 of the options granted, no earlier than 3 years after
the allocation date (iii) 1/3 of the options granted, no earlier than 4 years
after the allocation date. <br />
<br />
For further information, please contact:<br />
<br />
Hilja Ibert<br />
CEO, Gentian Diagnostics<br />
E-mail: hilja.ibert@gentian.no<br />
Cell Phone: +47 919 05 242<br />
<br />
Njaal Kind<br />
CFO, Gentian Diagnostics<br />
E-mail: njaal.kind@gentian.no<br />
Cell Phone. +47 919 06 525